GOODWILL AND INTANGIBLE ASSETS - Additional Information (Details) - USD ($)			3 Months Ended
		Oct. 05, 2015	Mar. 31, 2016	Mar. 31, 2015	Sep. 30, 2013	Jun. 30, 2013	Dec. 31, 2015	Oct. 31, 2015	Dec. 14, 2007
Summary of intangible assets [Abstract]
Maximum age of children for management of nephropathic cystinosis			6 years
Amortization charged to intangible assets			$ 132,000	$ 60,000
Intangible asset impairment recognized			39,600,000
Goodwill impairment							$ 0
IP license for QUINSAIR [Member]
Summary of intangible assets [Abstract]
Total intangible assets								$ 213,800,000
Contingent payment								$ 350,000,000
Encode Pharmaceuticals, Inc. [Member] | IP license for RP103 [Member]
Summary of intangible assets [Abstract]
Total intangible assets			$ 2,620,000				2,620,000		$ 2,600,000
Useful Life			20 years
Encode Pharmaceuticals, Inc. [Member] | UCSD license FDA and EC approval milestones [Member]
Summary of intangible assets [Abstract]
Total intangible assets			$ 1,250,000				1,250,000
Milestone payment based on drug approvals					$ 500,000	$ 800,000
Useful Life			14 years
Encode Pharmaceuticals, Inc. [Member] | Other Intangible Assets [Member]
Summary of intangible assets [Abstract]
Total intangible assets			$ 240,000				240,000
Useful Life			16 years
Intangible assets, amortization method			straight-line method
Tripex Pharmaceuticals LLC [Member]
Summary of intangible assets [Abstract]
Contingent payment		$ 350,000,000
Useful Life	[1]	132 months
Tripex Pharmaceuticals LLC [Member] | Developed Technology - QUINSAIR [Member]
Summary of intangible assets [Abstract]
Total intangible assets			$ 3,200,000				$ 3,200,000
Useful Life			11 years

[1] Recognized on a straight-line basis.